STOK News and Press, Stoke Therapeutics Inc.

2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-14 12:10:53 ET Summary Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a P...

2024-06-13 16:45:21 ET More on Stoke Therapeutics Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist Stoke Therapeutics prices upsized equity offering of $125M Stoke Therapeutics announces proposed public offering worth $75M ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...

2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Stoke Therapeutics, Inc. (NASDAQ: STOK) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 11.25% on the day to $14.24. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucle...

2024-05-06 11:53:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stoke Therapeutics (NASDAQ: STOK ) just reported results for the first quarter of 2024. Stoke Therapeutics reported earnings per share of -57 cents. This was above the ana...

2024-05-06 07:52:16 ET More on Stoke Therapeutics Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist Stoke Therapeutics prices upsized equity offering of $125M Stoke Therapeutics announces proposed public offering worth $75M ...

2024-04-29 08:20:32 ET More on Stoke Therapeutics Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist Stoke Therapeutics prices upsized equity offering of $125M Stoke Therapeutics announces proposed public offering worth $75M ...

– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial strategy and operations for life science companies – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the ...